Last reviewed · How we verify

HG-group

Medical University of Vienna · FDA-approved active Small molecule

HG-group is a histone deacetylase inhibitor.

HG-group is a histone deacetylase inhibitor. Used for Treatment of various cancers.

At a glance

Generic nameHG-group
SponsorMedical University of Vienna
Drug classHistone deacetylase inhibitor
TargetHistone deacetylase
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Histone deacetylase inhibitors, such as HG-group, work by blocking the action of histone deacetylases, which are enzymes that remove acetyl groups from histones. This leads to increased acetylation of histones, resulting in chromatin relaxation and increased gene expression. As a result, HG-group can induce cell cycle arrest and apoptosis in cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: